Kwang Dong Pharmaceutical Co., Ltd.

Total Valuation

Kwang Dong Pharmaceutical Co., Ltd. carries a market capitalization of 252.30B, placing it among publicly traded companies globally. Its enterprise value stands at 507.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Kwang Dong Pharmaceutical Co., Ltd. currently has 49.66M shares outstanding.

Valuation Ratios

Kwang Dong Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 14.97. The price-to-sales ratio is 0.19, and the price-to-book ratio stands at 0.56.

Enterprise Valuation

On an enterprise value basis, Kwang Dong Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 14.40 and an EV/FCF ratio of 6.44. The EV/Sales ratio of 0.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.40 provides insight into valuation relative to core operating earnings.

Financial Position

Kwang Dong Pharmaceutical Co., Ltd. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.28, indicating elevated leverage, while an interest coverage ratio of 3.16 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Kwang Dong Pharmaceutical Co., Ltd. posts a return on equity of 3.75 and a return on invested capital of 2.52.

Taxes

Over the trailing twelve months, Kwang Dong Pharmaceutical Co., Ltd. has paid 10.15B in income taxes, reflecting an effective tax rate of 31.41.

Stock Price Statistics

Kwang Dong Pharmaceutical Co., Ltd.'s stock has gained approximately 5.73356% over the past 52 weeks. The 50-day moving average sits at 6,892.00, while the 200-day moving average is 6,777.50.

Income Statement

Over the trailing twelve months, Kwang Dong Pharmaceutical Co., Ltd. generated 1.69T in revenue and converted that into 21.62B in net income, yielding earnings per share of 564.36. EBITDA reached 35.26B, while operating income came in at 35.26B.

Balance Sheet

Kwang Dong Pharmaceutical Co., Ltd. holds 182.71B in cash and equivalents against 301.19B in total debt, resulting in a net debt position of 188.65B. Total book value stands at 578.67B, with working capital of 157.86B providing operational flexibility.

Cash Flow

Kwang Dong Pharmaceutical Co., Ltd. produced 52.23B in operating cash flow over the past twelve months. After subtracting -19.02B in capital expenditures, free cash flow totaled 33.20B - equivalent to 845.30 per share.

Margins

Kwang Dong Pharmaceutical Co., Ltd. operates with a gross margin of 18.26, reflecting its pricing power and cost economics. The operating margin of 2.08 and net profit margin of 1.28 provide insight into operational efficiency.

Dividends & Yields

Scores

Kwang Dong Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.49, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.